Active, not recruitingPHASE1, PHASE2NCT05524883

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Studying Duchenne muscular dystrophy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dyne Therapeutics
Intervention
DYNE-251(drug)
Enrollment
86 enrolled
Eligibility
4-16 years · MALE
Timeline
20222029

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05524883 on ClinicalTrials.gov

Other trials for Duchenne muscular dystrophy

Additional recruiting or active studies for the same condition.

See all trials for Duchenne muscular dystrophy

← Back to all trials